Kineta is an emerging biotech company that is dedicated to developing next-generation immunotherapies to transform the lives of patients. With a focus on innate immunity, Kineta aims to address the major challenges in current cancer therapy by discovering and developing potentially differentiated immunotherapies. Unlike other companies in the field, Kineta's unique approach differentiates itself by emphasizing innate immunity rather than adaptive immunity and T-cell-focused therapies.

To achieve its mission, Kineta has established an Innate Immunity Development Platform, which aims to develop fully human antibodies to tackle the major mechanisms of cancer immune resistance. The company has a robust pipeline of potential novel immunotherapies, with drug candidates expected to enter the clinic soon and additional immuno-oncology assets in preclinical development. Kineta's success is driven by its experienced leadership team, talented research and development team, immuno-oncology focused scientific advisory board, enabling technology platform, and strong intellectual property position.

By leveraging their expertise in drug development and corporate finance, Kineta aims to bring new pharmaceutical therapies to market and create significant value for patients with cancer